Dr. Randall on Unmet Needs in Platinum-Resistant Ovarian Cancer

Video

Leslie M. Randall, MD, MAS, ​discusses the unmet need​s in platinum-resistant ovarian cancer.

Leslie M. Randall, MD, MAS, ​professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massey Cancer Center, VCU Health, discusses the unmet need​s in platinum-resistant ovarian cancer.

 Limited treatment options are available for patients with platinum-resistant ovarian cancer, representing a clear unmet need, explains Randall.

 Although chemotherapy is the standard of care, the response rate is approximately 15% in this setting, says Randall.

As such, the FDA accelerated approval pathway, which offers a potential opportunity to fulfill these unmet needs, still stands in the United States, Randall concludes.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD